Related Experiment Video
Updated: Oct 12, 2025

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Thrombosis in VEXAS syndrome
Thet Mon Oo1,2,3, Jie Tian Jeanette Koay4, Siew Fen Lee1
1Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore.
VEXAS syndrome, caused by a UBA1 mutation, significantly increases the risk of venous thromboembolism (VTE). Early VTE detection and management are crucial for patients with this autoinflammatory condition.
Area of Science:
- Rheumatology
- Hematology
- Genetics
Background:
- VEXAS syndrome is an autoinflammatory disorder characterized by somatic mutations in the UBA1 gene.
- Patients with VEXAS syndrome exhibit a substantial thrombotic risk.
Observation:
- A 69-year-old male diagnosed with VEXAS syndrome experienced venous thromboembolism (VTE).
- Literature review indicates VTE occurs in 36.4% of VEXAS patients, predominantly deep vein thrombosis, compared to arterial thrombosis (1.6%).
Findings:
- Somatic UBA1 gene mutations lead to reduced ubiquitylation.
- This reduction contributes to thrombosis via chronic inflammation, cytokine release, and dysregulated hemostasis.
- Abnormal interactions between immune cells, platelets, and endothelium cause endothelial dysfunction.
Implications:
- Targeting endothelial dysfunction and inflammation with immunosuppressants and immunomodulatory agents is a potential strategy.
- Combined with anticoagulation, this approach may prevent recurrent thrombotic events in VEXAS syndrome patients.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Esophageal Varices-I: Introduction
Varicose Veins I: Introduction

